169 Aufrufe 169 0 Kommentare 0 Kommentare

    Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

    • Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to count
    • A "FOR" vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 is required to allow for completion the proposed merger with TuHURA Biosciences

    SAN DIEGO, Sept. 18, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, is reminding stockholders to vote at the upcoming Special Meeting of Stockholders to be held on September 20, 2024 to allow for the completion of its proposed merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA").

    Kintara encourages stockholders to vote by 11:59 p.m. ET on Thursday, September 19, 2024, in order to obtain stockholder approval of the proposals to allow for completion of the proposed Merger.

    Our preliminary tabulation indicates the voting threshold has not been reached on Proposals 3 & 5. The proposed Merger cannot proceed unless holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 are voted FOR Proposals 3 & 5 (as described below).

    Prominent proxy advisory services, Institutional Shareholder Services and Glass Lewis, have both recommended stockholders vote "FOR" Proposals 3 & 5. 

    Robert E. Hoffman, Kintara's Chief Executive Officer, stated, "Your vote is crucial to our future and our mission to combat solid tumor cancers. By merging with TuHURA, we believe we can combine our oncology assets and technologies to overcome treatment resistance and accelerate our pipeline, backed by $31 million in financing. If the proposed Merger is not completed, the future of Kintara is uncertain."

    Proposal 3 is seeking stockholder approval of an amendment to Kintara's Articles of Incorporation, as amended, to increase the number of authorized shares of Kintara to be effected at such time and date as determined by the Kintara board of directors in its sole discretion.

    Proposal 5 is seeking stockholder approval of the reincorporation of Kintara from the State of Nevada to the State of Delaware and the plan of conversion attached to Kintara's definitive proxy statement and final prospectus filed with the Securities and Exchange Commission (the "SEC") on August 19, 2024 as Annex D, including the certificate of incorporation of Kintara post-reincorporation in Delaware attached thereto as Annex G.

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to countA "FOR" vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 is required to allow for …